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Summary
Ethanol and the neuroactive steroids have interactive neuropharmacological effects and chronic
ethanol administration blunts the ethanol-induced increase in neuroactive steroid levels in rodent
plasma and brain. Few studies have explored neuroactive steroid regulation in alcohol-dependent
human subjects. In fact, the regulation of adrenal neuroactive steroids has not been well defined in
healthy controls. We thus explored the regulation of two neuroactive steroids, pregnenolone sulfate
(PREG-S) and deoxycorticosterone, by pharmacological challenges to the hypothalamic-pituitary-
adrenal (HPA) axis in healthy controls and one-month abstinent alcohol-dependent patients with co-
occurring nicotine dependence. Plasma levels of PREG-S and deoxycorticosterone were measured
by radioimmunoassay in controls and alcohol-dependent patients after challenges of naloxone, ovine
corticotrophin releasing hormone (oCRH), dexamethasone, cosyntropin, and cosyntropin following
high-dose dexamethasone. In addition, basal diurnal measures of both hormones were obtained.
PREG-S plasma levels in healthy controls were increased by cosyntropin challenge (with and without
dexamethasone pretreatment) and decreased by dexamethasone challenge. However, PREG-S
concentrations were not altered by naloxone or oCRH challenges, suggesting that PREG-S is not
solely regulated by hypothalamic or pituitary stimulation. Deoxycorticosterone, in contrast, is
regulated by HPA challenge stimulation in a manner similar to cortisol. Alcohol-dependent patients
had a blunted PREG-S response to cosyntropin (with and without dexamethasone pretreatment).
Furthermore, the time to peak deoxycorticosterone response following oCRH was delayed in alcohol-
dependent patients compared to controls. These results indicate that plasma PREG-S and
deoxycorticosterone levels are differentially regulated by HPA axis modulation in human plasma.
Further, alcohol-dependent patients show a blunted PREG-S response to adrenal stimulation and a
delayed deoxycorticosterone response to oCRH challenge.
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Introduction
Neuroactive steroids are endogenous neuromodulators that rapidly alter neuronal excitability
by binding to membrane receptors (Paul and Purdy, 1992). Neuroactive steroids that are
synthesized directly in the brain, independent of peripheral sources and still detected in
adrenalectomized/orchiectomized animals, have been termed neurosteroids (Baulieu, 1998).
Pregnenolone sulfate (PREG-S) and deoxycorticosterone are endogenous neuroactive steroids
synthesized from cholesterol. Cholesterol is converted into pregnenolone by the mitochondrial
enzyme CYP11A and metabolized to PREG-S via a sulfotransferase enzyme. Alternately,
pregnenolone can be converted into progesterone which is further converted into
deoxycorticosterone, a precursor of the potent GABAA receptor agonists 3α21-dihydroxy-5α-
pregnan-20-one (3α,5α-THDOC) and 3α,5β-THDOC (Figure 1). Although these conversions
can take place in the brain (Stoffel-Wagner, 2001; Davies and MacKenzie, 2003), plasma levels
of these steroids measured in healthy human subjects are likely of adrenal origin. Therefore,
in this paper we will refer to PREG-S and deoxycorticosterone as neuroactive steroids as
opposed to neurosteroids.
Neuroactive steroids have potent effects on neurotransmission mediated by γ-aminobutyric
acid type A (GABAA) and/or glutamate receptors and transporters. PREG-S-is an excitatory
neuroactive steroid that inhibits GABA release at nanomolar concentrations (Mtchedlishvili
and Kapur, 2003), inhibits GABAA receptors, and potentiates N-methyl-D-aspartate (NMDA)
receptor-mediated excitatory responses at micromolar concentrations (Majewska et al., 1988;
Wu et al., 1991). PREG-S modulates learning and memory in rodents (Flood et al., 1992;
1995); its concentrations decrease with age and administration of PREG-S reverses cognitive
deficits in aged rats (Vallee et al., 2001). PREG-S also prevents the memory-impairing effects
of ethanol (Melchior and Ritzmann, 1996) and plays an important role in fetal alcohol syndrome
(Caldeira et al., 2004; Mameli and Valenzuela, 2006). PREG-S concentrations are increased
by corticotrophin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH)
challenges in rat brain and plasma (Torres and Ortega, 2003) and by ACTH challenge in
humans (De Peretti and Mappus, 1983; Boizel et al., 1986).
In contrast, deoxycorticosterone is an inhibitory neuroactive steroid with anticonvulsant
properties (Selye, 1942; Craig, 1966) that have been attributed to its conversion to 3α,5α-
THDOC, a potent GABAergic modulator (Reddy and Rogawski, 2002). Deoxycorticosterone
and 3α,5α-THDOC are increased following acute ethanol administration in rats (Barbaccia et
al., 1999; Khisti et al., 2005). In humans, deoxycorticosterone plasma levels are increased
following ACTH administration and decreased after dexamethasone administration (Brown
and Strott, 1971; Tan and Mulrow, 1975; Kater et al., 1990), suggesting potential regulation
by the hypothalamic-pituitary-adrenal (HPA) axis. In agreement, (Porcu et al. 2006a) have
shown that plasma deoxycorticosterone levels in cynomolgus monkeys are increased by
naloxone and CRH challenges and decreased by dexamethasone challenge.
Animal models of ethanol dependence show adaptations in stimulated neuroactive steroid
concentrations. Chronic ethanol consumption in rodents decreases corticosterone responses to
stress (Spencer and McEwen, 1990) and blunts ethanol challenge-induced elevation of plasma
and brain levels of the neuroactive steroids 3α-hydroxy,5-pregnan-20-one (3α,5α-THP) and
deoxycorticosterone (Morrow et al., 2001; Khisti et al., 2005). Following long-term ethanol
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self-administration in cynomolgus monkeys, basal deoxycorticosterone levels are elevated and
deoxycorticosterone responses to HPA axis modulation by CRH and dexamethasone are
blunted (Porcu et al., 2006b). In humans, Adinoff et al. (2005a,b) have shown that one-month
abstinent alcohol-dependent patients have decreased cortisol concentrations compared to
healthy controls. The cortisol responses to ovine CRH (oCRH) and dexamethasone plus
cosyntropin challenges were blunted in alcohol-dependent patients. In addition, both ACTH
and cortisol were suppressed to a greater extent in the alcohol-dependent patients after
dexamethasone challenge. Several other investigators (Adinoff et al., 1990; Wand and Dobs,
1991; Inder et al, 1995; Costa et al., 1996; Ehrenreich et al., 1997) have demonstrated an
attenuated glucocorticoid response in alcohol-dependent subjects following both psychosocial
and pharmacological challenges.
Despite both a sizable literature confirming a disruption in HPA axis regulation in alcohol-
dependent subjects and a link between HPA axis activation and neuroactive steroid release, no
studies of basal or stimulated levels of deoxycorticosterone or PREG-S in alcohol dependence
have been conducted to date. We therefore assessed PREG-S and deoxycorticosterone
responses to pharmacological challenges of the HPA axis in the healthy control and alcohol-
dependent subjects previously described by Adinoff et al. (2005a,b). The aims of the present
work were: a) to determine how the neuroactive steroids PREG-S and deoxycorticosterone
respond to hypothalamic, pituitary, and adrenal stimulation by pharmacological challenges
with naloxone, oCRH, cosyntropin, dexamethasone plus cosyntropin and dexamethasone alone
in healthy human subjects and, b) to determine if the HPA regulation of these neuroactive
steroids is altered in abstinent alcohol-dependent subjects.
A number of pharmacological challenges were used to selectively explore HPA axis
functioning in these studies. As background, activation of the HPA axis stimulates the release
of CRH from the hypothalamus. CRH induces the synthesis and release of ACTH from the
pituitary, which stimulates the adrenal gland to release glucocorticoids and neuroactive
steroids. Glucocorticoids, primarily cortisol in humans and non-human primates and
corticosterone in rodents, elicit negative feedback upon the hypothalamus and pituitary.
Likewise, the GABAergic neuroactive steroids inhibit CRH production, ACTH release and
corticosterone increase in rodents (Owens et al., 1992; Patchev et al., 1994; Patchev et al.,
1996). Thus, administration of naloxone was used to assess HPA axis activity by blocking the
inhibitory opioid input to CRH neurons in the hypothalamus. The pituitary ACTH response
was tested by administering oCRH, while the adrenal secretion of cortisol and neuroactive
steroids was assessed by administration of cosyntropin (synthetic ACTH, corticotrophin
α1–24). Administration of cosyntropin following high dose dexamethasone pretreatment also
tested the adrenal secretion after near complete suppression of endogenous pituitary ACTH
release. The dexamethasone suppression test further assessed the sensitivity of negative
feedback on pituitary corticotrophs.
Methods
Subjects
Twenty-one male alcohol-dependent participants were recruited from patients requesting
treatment for alcohol dependence at the Dallas VA Medical Center and Homeward Bound, Inc.
as previously reported (Adinoff et al., 2005a,b). Due to the volume of blood required, two
different populations of alcohol-dependent subjects were studied (Group 1: oCRH and
naloxone challenges, Group 2: cosyntropin and dexamethasone plus cosyntropin challenges).
Eleven patients (aged 43.5 ± 4.8 years [mean ± SD]; range, 36 – 49 years) participated in group
1. Ten patients (aged 42.8 ± 4.0 years [mean ± SD]; range, 38 – 49 years) participated in group
2. Patients reported an alcohol intake of at least 80 g of absolute alcohol on a daily basis for at
least two weeks before the cessation of drinking and had at least a 10-year history of
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problematic drinking. 90% of the patients were also nicotine-dependent. Patients with a lifetime
history of other DSM-IV (American Psychiatric Association, 1994) Axis I psychiatric disorders
(such as anxiety, post-traumatic stress, or mood disorders) not associated with alcohol use,
other substance use disorders (or weekly drug use) within the previous 12 months (excluding
caffeine or nicotine use disorders), active medical disorders (i.e., hypertension, diabetes,
chronic pain, or cardiac or pulmonary disorders), or a history of major head trauma were
excluded from the study. Furthermore, patients taking medications that may interfere with HPA
axis functioning (i.e. psychotropic, antihypertensive or hypoglycemic agents), patients with
Beck Depression Inventory (Beck et al., 1979) scores above 15 the week before testing, and
patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) three times
greater than the clinical laboratory’s upper limit of normal, were also excluded.
Fourteen healthy men were individually age-matched within a five-year period with alcohol-
dependent patients. Ten subjects (aged 38.2 ± 5.4 years [mean ± SD];range, 30 – 47 years)
underwent the naloxone and oCRH tests and eleven subjects (aged 39.6 ± 5.7 years [mean ±
SD]; range, 31 – 47 years) underwent the cosyntropin and dexamethasone plus cosyntropin
tests. Six subjects underwent all tests, with at least six weeks separating the two sets of
endocrine challenges. Controls reported no lifetime history of any DSM-IV axis I disorder
(except caffeine or nicotine use disorders), reported no medical disorders, and were taking no
medications. To avoid possible effects of family history of substance abuse or other psychiatric
disorders on HPA axis functioning, controls with a single first-degree relative or two second-
degree relatives with an axis I disorder were excluded.
All participants underwent a history and physical examination, clinical laboratory testing
(including complete blood count, liver function tests, routine blood chemistries, thyroid-
stimulating hormone test, and HIV test), electrocardiography, and urine drug screening. The
study was conducted in accordance with the Declaration of Helsinki
(http://www.wma.net/e/ethicsunit/helsinki.htm) and was approved by the Institutional Review
Boards at both the University of Texas Southwestern Medical Center and the Dallas VA
Medical Center. Informed consent was obtained after the study was fully explained, and
participants were financially compensated for their participation.
Neuroendocrine Challenge Tests
All neuroendocrine studies were performed at the General Clinical Research Center (GCRC)
at the University of Texas Southwestern Medical Center as previously described (Adinoff et
al., 2005a,b). Both healthy controls and alcohol-dependent participants arrived at the GCRC
at least two hours before the studies. Alcohol-dependent patients were accompanied to the
GCRC from their treatment site. The studies were performed in separate sessions and session
order was balanced. Nicotine-dependent subjects were placed on nicotine patches appropriate
to their daily cigarette intake upon admission to the GCRC so that nicotine withdrawal
symptoms were avoided.
Blood samples were obtained every ten min for 30 min prior to pharmacological challenge.
Blood samples were then obtained every five min during the first hour and every 10 min during
the second hour following challenge infusion. PREG-S and deoxycorticosterone were post-
hoc assays run on those time points where sufficient plasma was available. Samples from two
to three different time points were combined to obtain sufficient plasma for the analysis
[samples from 2035h, 2040h and 2045h or from 2100h and 2110h were combined and the mean
interval (i.e. 2040h or 2105h) is shown in the figures].
Group 1—These tests have previously been described in Adinoff et al. (2005b).
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oCRH challenge: Participants were admitted to the GCRC at 1800h on day one. An
intravenous catheter was inserted in each arm at 0700h on day two. Blood sampling was
initiated for pulsatile measures of ACTH and cortisol one hour later (at 0800h) and continued
through 2000h. Blood sampling at 1915h was used as baseline for PREG-S and
deoxycorticosterone determinations. After the collection of the final basal measure at 2000h,
0.4 µg/kg oCRH was administered IV over one min. oCRH was administered at 2000h during
the glucocorticoid diurnal troughs.
Naloxone challenge: Participants returned to the GCRC by 1700h, two days after the
completion of the oCRH challenge. An intravenous catheter was placed in both arms at
approximately 1800h on the day of the study. Basal measures of ACTH and cortisol were
obtained from 1900h to 2000h, and the 1940h was used for baseline PREG-S and
deoxycorticosterone determinations. Naloxone 125 µg/kg was administered IV over one min
immediately after the 2000h blood withdrawal. One patient did not return to the GCRC for the
naloxone challenge after completion of the oCRH challenge.
Group 2—All subjects were administered both the Cosyntropin challenge and the
Dexamethasone plus Cosyntropin challenge. Challenges were administered seven days apart.
Test order was randomly determined and balanced between groups (described in Adinoff et
al., 2005a).
Cosyntropin challenge: Participants were brought to the GCRC at 1800h on day one. A 24-
h urine collection was initiated at 2000h on day one for urinary free cortisol and continued
until 2000h on day two. An intravenous catheter was inserted in each arm at 1900h on day two.
One hour later (at 2000h) blood sampling was initiated for 12-h basal measures of ACTH and
cortisol and continued through 0800h on day three. Blood sampling at 0715h was used as
baseline for PREG-S and deoxycorticosterone determinations. After the 0800h blood
withdrawal on day three, 0.01 µg/kg cosyntropin was administered IV over one min.
Dexamethasone plus Cosyntropin challenge: This study included the pituitary and
adrenocortical response to dexamethasone and the cosyntropin challenge after dexamethasone.
Participants arrived at the GCRC at 2000h and intravenous lines were placed into both arms
at 2100h. Blood samples for the measurement of ACTH and cortisol were obtained every 10
min from 2200h through 2300h. Dexamethasone 8 mg in 50 ml of dextrose 5% water (D5W)
was administered IV from 2300h to 2330h. Blood sampling was continued from 2300h to
0500h and then restarted at 0700h to 0800h every 10 min (blood sampling was not obtained
from 0500h to 0700h because of limitations on blood volume). The cosyntropin challenge was
performed as described above.
Assays
PREG-S assay—PREG-S levels were determined by radioimmunoassay (RIA) as follows.
Plasma samples (250 µl) were extracted three times with 2 ml diethyl ether to remove free
pregnenolone and 3α,5α-THP from the sample. [3H]pregnenolone (1000 cpm; SpA = 14 Ci/
mmol; Perkin Elmer Life Sciences, Boston, MA, USA) and [3H]PREG-S (1000 cpm; SpA =
20 Ci/mmol; Custom synthesis from American Radiolabeled Chemicals, Inc., Saint Louis, MO,
USA) were added to each sample for recovery estimation and to confirm that diethyl ether
selectively extracted free pregnenolone, while the PREG-S was left in the aqueous phase.
However, a percentage of [3H]pregnenolone was found in the aqueous phase (1.0 ± 0.6%).
These values were incorporated in the recovery estimates. The aqueous phase was then purified
with OASIS HLB cartridges (60 mg; Waters Chromatography, Milford, MA, USA), as
described by Higashi et al. (2003). Prior to use, cartridges were conditioned with 1 ml ethyl
acetate, 2 ml ethyl alcohol (100%) and 2 ml double-distilled water. The aqueous phase was
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then applied to the cartridge and washed with 2 ml double-distilled water followed by 1 ml
ethyl acetate. PREG-S was eluted with 1.5 ml ethyl alcohol and samples were dried in a speed
vacuum concentrator. The dried extracts were resuspended in 2 ml RIA buffer of which 0.5 ml
was used for the assay (run in duplicate) and for recovery determination. Average final recovery
of PREG-S was 82 ± 0.9%. The antiserum for PREG-S was purchased from MP Biomedicals
(Orangeburg, NY, USA) and diluted according to manufacturer’s instructions. This antiserum
cross-reacts 100% with pregnenolone and PREG-S; it also cross reacts with 3α,5α-THP 16%,
3α,5β-THP 5.9%, progesterone 3.1%, 3α,5α-THDOC 1.1%. Less than 1% cross-reactivity was
observed for 5α-dihydroprogesterone, 17α-hydroxyprogesterone, 20α-dihydroprogesterone,
17α-hydroxypregnenolone, deoxycorticosterone, cortisol, 11-deoxycortisol, corticosterone,
androsterone, 5α-dihydrotestosterone, cholesterol, 17β-estradiol, estrone and estriol. Unknown
samples are compared to concurrently run standards for PREG-S using a one-site competition
model and adjusted for extraction efficiency. Values are expressed as ng/ml plasma. The
sensitivity of the assay is 50 pg/ml. Intra-assay and inter-assay coefficients of variation were
12.1% and 14.3%, respectively.
Deoxycorticosterone assay—Deoxycorticosterone levels were determined by RIAas
previously described (Porcu et al., 2006a). Briefly, plasma samples (200 µl) were extracted
twice with 2 ml ethyl acetate/hexane (3:2) 1000 cpm aliquot of [3H]deoxycorticosterone (SpA
= 50 Ci/mmol; American Radiolabeled Chemicals, Inc. Saint Louis, MO, USA) was added to
each sample for recovery estimation. The dried extracts were resuspended in 1.5 ml RIA buffer
of which 0.5 ml was used for the assay (run in duplicate) and 0.3 ml was used for recovery
determination. The antiserum for deoxycorticosterone was purchased from MP Biomedicals
(Orangeburg, NY, USA) and diluted according to manufacturer’s instructions. This antiserum
was highly specific for deoxycorticosterone as shown by the following cross-reactivity tests:
deoxycorticosterone 100%, 3α,5α-THDOC 4.7%, progesterone 2.5%, corticosterone 1.7%.
Less than 1% cross-reactivity was observed for 3α,5α-THP, 3α-hydroxy-pregn-4-en-20-one,
pregnenolone, 20-hydroxy-pregnen-4,3-one, testosterone, androstenedione, 17α-
hydroxyprogesterone, 11-deoxycortisol, 5α-dihydrotestosterone, cortisol, cholesterol, 17β-
estradiol, estrone and estriol. Unknown samples were compared to concurrently run standards
using a one-site competition model and adjusted for extraction efficiency. Deoxycorticosterone
values are expressed as ng/ml plasma. The sensitivity of the assay is 10 pg/ml. Intra-assay and
inter-assay coefficients of variation were 4.86% and 4.51%, respectively.
Data Analysis
Steroid levels were analyzed using a commercially available statistical program (GraphPad
Prism 4.0, GraphPad Software, San Diego, CA, USA). ANOVAs were performed on log-
transformed values to control for potential heterogeneity of variance. Two-way repeated
measures ANOVAs considering the factors group (control vs. patient) and time, as the repeated
factor, were performed. Two-way ANOVAs were performed when missing values did not
allow the repeated measures test. Post-hoc comparisons were performed by the Bonferroni test.
Values are expressed as mean ± SEM of the raw data and p values less than 0.05 were
considered statistically significant. Net area under the curve (AUC) was calculated using Sigma
Plot 8.0 (Systat Software, Inc., Point Richmond, CA, USA). PREG-S, deoxycorticosterone,
and cortisol peak responses (% increase vs. basal) to each challenge test were correlated using
the Pearson’s coefficient.
Results
Baseline and Diurnal Cycle of PREG-S and deoxycorticosterone
Demographic characteristics of participants are shown in Table 1 and were previously
described in Adinoff et al. (2005a,b).
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Differences in the diurnal secretion of PREG-S and deoxycorticosterone plasma levels were
determined from morning (0715h) and evening (1915h) basal values prior to the cosyntropin
and the oCRH and naloxone challenges, respectively. Two-way ANOVA for PREG-S showed
no significant effect of time (0715h vs. 1915h) [F(1,18)=0.13; p=0.73], no significant effect
of group (controls vs. alcohol-dependent patients) [F(1,18)=0.36; p= 0.56] and no significant
interaction [F(1,18)=0.02; p=0.89]. PREG-S levels did not show a diurnal variation in either
healthy controls or alcohol-dependent patients. Furthermore, no differences were observed in
PREG-S basal values between abstinent alcohol-dependent subjects vs healthy controls (Figure
2A).
In contrast, two-way ANOVA for deoxycorticosterone revealed a significant effect of time
(0715h vs. 1915h) [F(1,18)=31.17; p<0.0001] but no effect of group (controls vs. alcohol-
dependent patients) [F(1,18)=0.90; p=0.35] or significant interaction [F(1,18)=2.49; p=0.12].
Thus, deoxycorticosterone levels were lower in the evening relative to the morning [50% lower
in controls and 30% lower in alcohol-dependent patients, respectively]. However, no
differences were observed between controls and alcohol-dependent patients (Figure 2B).
HPA Axis Regulation of PREG-S and Deoxycorticosterone Levels
Naloxone challenge—PREG-S and deoxycorticosterone measures were determined 20 min
before and 40, 55, 65, 85, 105 and 120 min following naloxone infusion (125 µg/kg, IV).
Two-way repeated measures ANOVA for PREG-S found a significant effect of time [F(6,18)
=4.34; p=0.0005], but no effect of group (controls vs. alcohol-dependent patients) [F(1,18)
=0.17; p=0.68] or significant interaction [F(6,18)=0.24; p=0.96]. However, PREG-S levels did
not significantly differ from basal measures in either healthy controls or alcohol-dependent
patients (Figure 3A).
Two-way repeated measures ANOVA for deoxycorticosterone also revealed a significant
effect of time [F(6,18)=7.25; p<0.0001], but no effect of group (controls vs. alcohol-dependent
patients) [F(1,18)=0.87; p=0.36] or significant interaction [F(6,18)=0.51; p=0.80]. Naloxone
increased deoxycorticosterone levels in both groups compared to basal measurements (Figure
3B). In healthy controls, deoxycorticosterone levels peaked 55 min after naloxone
administration (+81%) and remained significantly elevated at 65 and 85 min (+47 and +55%,
respectively). In alcohol-dependent patients, deoxycorticosterone levels were increased by
62% at 55 min, peaked at 65 min (+72%) and were still elevated at 85 min (+56%).
oCRH challenge—PREG-S and deoxycorticosterone measures were determined 45 min
before and 55, 65, 85, 105 and 120 min following oCRH infusion (0.4 µg/kg, IV). Only
deoxycorticosterone levels were measured at 40 min due to insufficient plasma availability for
the PREG-S assay.
Two-way ANOVA for PREG-S showed a significant effect of time [F(5,18)=2.61; p=0.03],
but no effect of group (controls vs. alcohol-dependent patients) [F(1,18)=2.79; p=0.10] or
significant interaction [F(5,18)=0.43; p=0.82]. Indeed, PREG-S levels following oCRH did
not change in healthy controls or alcohol-dependent patients relative to the basal measure
(Figure 4A).
Two-way ANOVA for deoxycorticosterone revealed a significant effect of time [F(6,18)
=19.23; p<0.0001], no effect of group (controls vs. alcohol-dependent patients) [F(1,18)=0.30;
p=0.58], but a significant interaction between group and time variables [F(6,18)=3.42;
p=0.004]. oCRH increased deoxycorticosterone levels in both controls and alcohol-dependent
patients compared to the 45 min pre-drug basal values (Figure 4B). In the control group,
deoxycorticosterone levels were significantly increased at all time points following oCRH
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infusion with the peak occurring at 40 min (+224%). In alcohol-dependent patients,
deoxycorticosterone levels were elevated at 40 min (+44%), peaked at 85 min (+161%) and
remained increased at 105 and 120 min (+136 and 156%, respectively). Furthermore,
deoxycorticosterone levels were 52% lower in alcohol-dependent patients 40 min following
oCRH administration compared to the respective time point in the control group. Further
analysis revealed that the time to peak response following oCRH administration was shifted
in alcohol-dependent patients compared to controls; the mean time for peak response in controls
was 50 min, compared to 87 min in alcohol-dependent patients (Figure 4C).
Cosyntropin challenge—Blood samples for PREG-S and deoxycorticosterone measures
were taken 45 minutes before and 50 to 55 min following cosyntropin (0.01 µg/kg, IV)
administration.
Two-way repeated measures ANOVA for PREG-S revealed a significant effect of time [F
(1,18)=19.42; p=0.0003], no effect of group (controls vs. alcohol-dependent patients) [F(1,18)
=1.90; p=0.19] and a significant interaction [F(1,18)=9.14; p=0.007]. PREG-S levels increased
by 49% in healthy controls 55 min after infusion, but did not change in alcohol-dependent
patients (Figure 5A).
Two-way repeated measures ANOVA for deoxycorticosterone revealed a significant effect of
time [F(1,18)=26.86; p<0.0001], but no effect of group (controls vs. alcohol-dependent
patients) [F(1,18)=4.23; p=0.055] and no interaction [F(1,18)=0.08; p=0.78]. Cosyntropin
administration increased deoxycorticosterone levels in both healthy controls (+66%) and
alcohol-dependent patients (+37%) 55 min after infusion compared to the respective pre-drug
basal values (Figure 5B).
Dexamethasone plus Cosyntropin challenge—In this test, cosyntropin was
administered nine hours following dexamethasone (8 mg, IV) and blood samples were obtained
45 minutes before and 30 and 55 minutes after cosyntropin.
Two-way ANOVA for PREG-S revealed a significant effect of time [F(2,18)=15.90;
p<0.0001], a significant effect of group (controls vs. alcohol-dependent patients) [F(1,18)
=14.24; p=0.0004] but no significant interaction [F(2,18)=0.09; p=0.92]. PREG-S levels were
increased in both groups 30 and 55 min following cosyntropin administration compared to
their respective basal values prior to cosyntropin (and after dexamethasone). In healthy
subjects, PREG-S levels were increased by 141% and by 68% at 30 and 55 min, respectively,
following cosyntropin. In alcohol-dependent patients, PREG-S increased by 113% and by
105% at 30 and 55 min, respectively, following cosyntropin (Figure 6A). Despite the ANOVA
showing a significant effect of group, the post-hoc analysis failed to reveal any significance
between controls and alcohol-dependent subjects. However, further analysis using the net area
under the curve (AUC) revealed that PREG-S AUC in alcohol-dependent patients was
significantly lower than controls (−38%, Figure 6B).
For deoxycorticosterone, two-way ANOVA revealed a significant effect of time [F(2,18)=1.68;
p<0.0001], but no effect of group (controls vs. alcohol-dependent patients) [F(1,18)=0.09;
p=0.11] or significant interaction [F(2,18)=0.01; p=0.78]. Cosyntropin administration nine
hours after dexamethasone increased deoxycorticosterone levels in both controls and alcohol-
dependent patients compared to their respective pre-cosyntropin basal values. In healthy
subjects, deoxycorticosterone levels were increased by 281% and by 100% 30 and 55 min,
respectively, after cosyntropin infusion; in alcohol-dependent patients, deoxycorticosterone
was increased by 335% and by 151%, respectively (Figure 6C).
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Dexamethasone Challenge—The effect of dexamethasone alone on PREG-S and
deoxycorticosterone levels was evaluated by comparing the 0715h baseline from the
cosyntropin stimulation test alone and the one obtained nine hours after dexamethasone but
before cosyntropin administration.
Two-way repeated measures ANOVA for PREG-S revealed a significant effect of time [F
(1,18)=70.03; p<0.0001], no effect of group (controls vs. alcohol-dependent patients) [F(1,18)
=2.43; p=0.14] and no interaction [F(1,18)=2.99; p=0.10]. Dexamethasone decreased PREG-
S levels by 47% in control subjects and by 64% in alcohol-dependent patients (Figure 7A).
Two-way repeated measures ANOVA for deoxycorticosterone revealed a significant effect of
time [F(1,18)=36.70; p<0.0001], a significant effect of group (controls vs. alcohol-dependent
patients) [F(1,18)=6.94; p=0.012] but no interaction [F(1,18)=0.03; p=0.86].
Deoxycorticosterone levels were decreased by 43% in control subjects and by 44% in alcohol-
dependent patients compared to their respective basal values (Figure 7B). Again, despite the
ANOVA finding a significant effect of group, the post-hoc test failed to reveal any significant
differences between controls and alcohol-dependent subjects.
Correlations among Neuroendocrine Measures
We analyzed potential correlations between the PREG-S and deoxycorticosterone peak
responses obtained in these subjects following each pharmacological challenge and the cortisol
peak responses reported by Adinoff et al. (2005a,b). Data from healthy controls and alcohol-
dependent subjects were combined, given the lack of significant differences in the correlations
between the two groups. Time points of peak responses were variable for each steroid. The
peak percent increase in PREG-S was correlated with the peak percent increase in
deoxycorticosterone following the naloxone, cosyntropin and dexamethasone plus cosyntropin
challenges (r=0.48, p=0.034; r=0.46, p=0.049; r=0.64, p=0.001, respectively). The peak
percent increase in PREG-S was correlated with the peak percent increase in cortisol following
the cosyntropin challenge only (r=0.47, p=0.037). The peak percent increase in
deoxycorticosterone was correlated with the peak percent increase in cortisol following the
naloxone, oCRH and cosyntropin challenges (r=0.50, p=0.026; r=0.68, p=0.001; r=0.65,
p=0.003, respectively).
Discussion
Little is known about HPA axis regulation of neuroactive steroid synthesis in humans. In this
study, we show that PREG-S levels are regulated by adrenal activation of the HPA axis and
are sensitive to negative feedback mechanisms; however, they do not exhibit diurnal variation
or significantly change after naloxone and oCRH infusions. In contrast, deoxycorticosterone
levels exhibit diurnal variations and are regulated by the HPA axis at all levels examined.
Abstinent alcohol-dependent patients, primarily nicotine dependent, have blunted PREG-S
response to adrenal stimulation with cosyntropin, butno other alterations in PREG-S and
deoxycorticosterone responses to HPA axis challenges were found (see Table 2 for
recapitulative results). To the best of our knowledge, this is the first comprehensive study of
the selective modulation of the HPA axis with naloxone, oCRH, cosyntropin and
dexamethasone on PREG-S and deoxycorticosterone levels in men.
The finding that naloxone or oCRH challenges did not alter PREG-S levels could indicate that
PREG-S levels are independent of hypothalamic or pituitary activation of the HPA axis. This
would explain the lack of diurnal changes in circulating PREG-S levels that we and others
(Laatikainen and Vihko, 1968) have observed in humans. The lack of change in PREG-S levels
following naloxone or oCRH stimulation in humans could be due to the preferential metabolism
of pregnenolone to progesterone (ratherthan PREG-S) mediated by an effect of naloxone or
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oCRH on the steroidogenic enzymes sulfotransferase and sulfatase that interconvert
pregnenolone and PREG-S. Indeed, naloxone, but not CRH, increases plasma pregnenolone
levels in cynomolgus monkeys (Porcu et al., 2006c). However, CRH does increase
progesterone and its neuroactive metabolite 3α,5α-THP in humans (Genazzani et al., 1998),
suggesting that CRH may promote pregnenolone metabolism to progesterone rather than
PREG-S. Alternatively, it is possible that activation of the HPA axis via hypothalamic or
pituitary stimulation induces the release of other hormones, in addition to ACTH, that could
interfere with PREG-S biosynthesis. For instance, it is known that ACTH derives from a large
precursor molecule, pro-opiomelanocortin, that gives rise to numerous hormones, including
opioid peptides and melanocyte stimulating hormone (Raffin-Sanson et al., 2003).
In contrast to PREG-S, deoxycorticosterone had a circadian variation (Tan and Mulrow,
1975) which is similar to that observed for ACTH and cortisol in the same subjects (Adinoff
et al., 2005a). Furthermore, plasma deoxycorticosterone and cortisol appear to be similarly
regulated by challenges to the HPA axis, as shown by the correlations in deoxycorticosterone
and cortisol responses following naloxone, oCRH, and cosyntropin challenges. In addition,
naloxone, oCRH, cosyntropin and cosyntropin following dexamethasone all significantly
increase deoxycorticosterone levels and dexamethasone decreases deoxycorticosterone levels.
These findings are consistent with other studies assessing deoxycorticosterone response to
pharmacological challenges (Brown and Strott, 1971; Tan and Mulrow, 1975; Kater et al.,
1990).
The second aim of this study was to explore putative differences in basal and stimulated PREG-
S and deoxycorticosterone levels between control subjects and abstinent alcohol-dependent
patients. The finding that basal PREG-S did not differ between healthy controls and abstinent
alcohol-dependent patients contrasts with a previous study showing higher plasma PREG-S
levels in premenopausal women undergoing alcohol detoxification treatment compared to
controls (Hill et al., 2005). Either sex differences or length of abstinence could be responsible
for this discrepancy. The blunted PREG-S response in alcohol-dependent patients following
cosyntropin is similar to the blunted cortisol response observed in the same subjects by Adinoff
et al. (2005a) (following dexamethasone pretreatment) and Wand and Dobs (1991) (without
dexamethasone pretreatment). Other experimental evidence suggests that suppressed PREG-
S levels might be relevant in alcoholism. Administration of PREG-S to rodents improves
cognition (Vallee et al., 2001) and cognitive impairment has been observed inalcoholics (Bates
et al., 2002). In agreement, PREG-S prevents the memory-impairing effects of ethanol in mice
(Melchior and Ritzmann, 1996). Therefore, diminished PREG-S responses to adrenal
activation may contribute to cognitive impairment in alcoholism.
Overall, we did not observe significant differences in basal or stimulated deoxycorticosterone
levels between controls and alcohol-dependent subjects. Basal deoxycorticosterone levels have
never previously been measured in alcohol-dependent subjects. In cynomolgus monkeys basal
deoxycorticosterone levels were dramatically increased after long-term alcohol exposure
(Porcu et al., 2006b). Furthermore, cynomolgus monkeys show a blunted deoxycorticosterone
response to CRH and dexamethasone challenges (Porcu et al., 2006b). In addition, rats after
chronic ethanol exposure had blunted deoxycorticosterone responses to an acute ethanol
challenge (Khisti et al., 2005). These discrepancies might be the result of species differences
or they might be due to different experimental conditions: assessment immediately following
chronic alcohol exposure in rats and cynomolgus monkeys versus one-month abstinence in
humans. In addition, more subtle findings of deoxycorticosterone alterations in the one-month
abstinent alcohol-dependent patients, including a delayed response to oCRH and a non-
statistically significant (p=0.055) suppressed response to cosyntropin, may yield significant
differences in future studies with a more thorough time course and increased group size.
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A methodological strength of this study is the population. Patients and controls were similar
in age and race. Although there was a statistically significant difference in age between the
two groups, the HPA axis remains functioning stable over this age range. Neither group had
significant medical disorders nor was taking any psychotropic drugs or other medications.
Period of abstinence in alcohol-dependent patients was controlled such that the study occurred
within four-six weeks after the last drink. However, alcohol-dependent patients were almost
all nicotine-dependent while controls were not. Although a previous study reported that
cigarette smoking in abstinent alcohol-dependent subjects did not alter the pituitary-adrenal
response to a pharmacological challenge (Anthenelli et al., 2001), a more recent study found
that 3α,5α-THP levels may be up-regulated in smokers and dehydroepiandrosterone sulfate
levels may predict nicotine dependence (Marx et al., 2006). Indeed, acute administration of
nicotine alters pregnenolone, progesterone, 3α,5α-THP and 3α,5α-THDOC levels in rat brain
and plasma (Porcu et al., 2003).
The major limitation of the study is that we had only few time points available; thus, our basal
measures preceded the challenge infusions by 20 to 45 min and time points after the infusion
were analyzed based on plasma availability. Therefore, it is possible that we may have missed
the actual peak level of PREG-S and deoxycorticosterone. Other limitations include the high
prevalence of psychologicalstress (divorced, unemployed, homeless) in the alcohol-dependent
group, although these subjects did not meet criterion for depression or anxiety disorders. Stress
is known to interfere with HPA axis functioning and we cannot rule out the possibility that the
alterations in PREG-S and deoxycorticosterone responses to HPA axis challenge seen in these
patients are strictly related to the alcohol-dependence. Also, recent findings using highly
sensitive mass spectrometry techniques suggest that PREG-S is not present in rat brain and
plasma (Liu et al., 2003; Liere et al., 2004). However, these authors were able to measure
PREG-S levels in human plasma and values are comparable to the ones we obtained using a
radioimmunoassay with a commercially available antibody.
In conclusion, we have shown that HPA axis modulation by pharmacological challenges
differentially regulates the neuroactive steroids PREG-S and deoxycorticosterone in humans.
The small number of subjects is a limitation that precludes definitive conclusions and argues
for further studies in alcohol-dependent subjects, examining other stages of alcohol dependence
(we only looked at one-month abstinent alcohol-dependent patients) and women. Moreover,
since deoxycorticosterone is the precursor of other GABAergic neuroactive steroids, it is
possible that its metabolites, or other pregnenolone metabolites, may be altered in alcohol
dependence. Nonetheless, these results add new information on neuroactive steroids in alcohol-
dependent subjects; since neuroactive steroids influence ethanol sensitivity (Morrow et al.,
2006), they might contribute to the underlying pathology.
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Schematic representation of the neuroactive steroids biosynthetic pathway from human adrenal
glands.
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Diurnal baseline plasma PREG-S (A) and deoxycorticosterone (B) levels in control subjects
(n=10) and alcohol-dependent patients (n=11). Data (mean ± SEM) are expressed as ng/ml.
Asterisks indicate significant difference between the time points: *p<0.05 and **p<0.001 (two-
way ANOVA).
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Time course of plasma PREG-S (A) and deoxycorticosterone (B) levels in control subjects
(n=10) and alcohol-dependent patients (n=10) after administration of naloxone (125 µg/kg,
IV) at 2000h. Data (mean ± SEM) are expressed as ng/ml. Letters indicate significant difference
from basal measures: ap<0.05, bp<0.01 and cp<0.001 vs. −20 min for control subjects; dp<0.01
and ep<0.001 vs. −20 min for alcohol-dependent patients (two-way repeated measures
ANOVA).
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Time course of plasma PREG-S (A) and deoxycorticosterone (B) levels in control subjects
(n=10) and alcohol-dependent patients (n=11) after administration of oCRH (0.4 µg/kg, IV)
at 2000h. Data (mean ± SEM) are expressed as ng/ml. Asterisk indicates significant difference
between controls and alcohol-dependent patients: *p<0.001; letters indicate significant
difference from basal measures: ap<0.001 vs. −45 min for control subjects; bp<0.05
and cp<0.001 vs. −45 min for alcohol-dependent patients (two-way ANOVA). (C) Data (mean
± SEM) represent the mean time interval (minutes) necessary to reach the deoxycorticosterone
peak response after administration of oCRH in control subjects and alcohol-dependent patients
(*p=0.0023, paired t test).
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Effect of cosyntropin on plasma PREG-S (A) and deoxycorticosterone (B) levels incontrol
subjects (n=10) and alcohol-dependent patients (n=11). Cosyntropin (0.01 µg/kg, IV) was
administered at 0800h. Data (mean ± SEM) are expressed as ng/ml. Asterisks indicate
significant differences between basal and cosyntropin groups: *p<0.01 and**p<0.001 vs. the
respective basal group (two-way repeated measures ANOVA).
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Time course of plasma PREG-S (A) and deoxycorticosterone (C) levels in control subjects
(n=10) and alcohol-dependent patients (n=11) after administration of dexamethasone plus
cosyntropin. Dexamethasone (8 mg, IV) was administered at 2300h; cosyntropin (0.01 µg/kg,
IV) was administered at 0800h the following day. Data (mean ± SEM) are expressed as ng/ml.
Letters indicate significant difference from basal measures: ap<0.05 and bp<0.01 for control
subjects; cp<0.01 and dp<0.001 for alcohol-dependent patients; ep<0.001 for both groups (two-
way ANOVA). Section B shows the PREG-S area under the curve (AUC) for controls and
alcohol-dependent patients following dexamethasone plus cosyntropin administration.
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Asterisk indicates significant difference between controls and alcohol-dependent patients:
*p=0.037 (Unpaired t test).
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Effect of dexamethasone on plasma PREG-S (A) and deoxycorticosterone (B) levels incontrol
subjects (n=10) and alcohol-dependent patients (n=11). Dexamethasone (8 mg, IV) was
administered at 2300h and PREG-S and deoxycorticosterone levels were measured nine hours
later. Basal levels were obtained from a 0715h sample. Data (mean ± SEM) are expressed as
ng/ml. Asterisks indicate significant differences between basal and dexamethasone groups:
*p<0.001 vs. the respective basal group (two-way repeated measures ANOVA).
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Table 1
Demographic and clinical characteristics of alcohol-dependent participants and healthy controls.
 Group 1 Group 2
 Patients (n = 11) Controls (n = 10) Patients (n = 11) Controls (n = 10)
Age (years) 43.5 ± 4.8 38.2 ± 5.4 42.8 ± 4.0 39.6 ± 5.7
Race     
   Asian 0 1 0 1
   White 8 8 6 7
   African-American 3 0 3 1
   Hispanic 0 1 2 1
Marital status     
   Single 1 0 0 2
   Married 0 5 1 7
   Separated 1 0 4 0
   Divorced 9 1 6 1
Employed 6 10 3 10
Homeless 3 0 8 0
Education (years) 12.3 ± 1.7 16.9 ± 2.8 13.0 ± 1.3 16.4 ± 2.9
Nicotine dependence 10 0 9 1
Beck Depression Score 10.3 ± 7.8 0.7 ± 1.6 8.0 ± 4.2 0.9 ± 1.7
ALT (units/liter) 24.8 ± 18.2 27.7 ± 12.0 59.0 ± 60.5 31.1 ± 10.4
AST (units/liter) 21.6 ± 8.5 24.1 ± 6.0 57.1 ± 47.6 33.8 ± 27.0
DrInC* 34.1 ± 10.7 3.1 ± 2.8 37.6 ± 6.3 3.7 ± 3.5
Years problem drinking 23.9 ± 5.4  20.8 ± 5.8  
Drinks in past 30 days 637 ± 331  853 ± 577  
Lifetime drinks 146193 ± 82485  131129 ± 106528  
Table is adapted from Adinoff et al., 2005a,b.
Data are mean ± Standard Deviation.
*
Drinker Inventory of Consequences
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Table 2
Recapitulative table of results.
 PREG-S Deoxycorticosterone
 Controls Patients Controls Patients
Basal measures No change No change Evening decrease Evening decrease
Naloxone challenge No change No change Increase Increase
oCRH challenge No change No change Increase Delayed increase*
Cosyntropin challenge Increase No change* Increase Increase
Dexamethasone plus
cosyntropin challenge
Increase Blunted increase* Increase Increase
Dexamethasone challenge Decrease Decrease Decrease Decrease
Summary of the pharmacological effects of each challenge on PREG-S and deoxycorticosterone plasma levels in healthy subjects (Controls) and one
month abstinent alcohol-dependent subjects (Patients). Asterisks indicate significant differences between controls and patients.
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